JB Chemicals ties up with US firm for anti-HIV drug
By agencies | Friday, 22 September 2006, 07:00 Hrs
MUMBAI: JB Chemicals & Pharmaceuticals Ltd on Friday said it has signed a non-exclusive licence agreement with US-based Gilead Sciences Inc to manufacture and distribute a generic version of the anti-HIV drug Tenofovir Disoproxil Fumarate.
Tenofovir, an anti retroviral drug, is useful in cases which are resistant to other anti-retroviral agents and is indicated for the treatment of HIV-1 infection in adults.
As per terms of the agreement, Gilead has granted the company a non-exclusive licensing right to manufacture and distribute generic versions of Tenofovir to 95 countries including India.
The company would register and distribute the drug on its own or through its partners in these countries, it said.
"Through this product, we will be able to meet the needs of patients suffering from HIV in India and in many low-income countries and will continue to expand our basket of ARV products through internal development and licensing agreements to meet the unm et needs of patients suffering from HIV," Mr J B Mody, Chairman and Managing Director, JB Chemicals, said.
Tenofovir disoproxil fumarate is sold by Gilead under the brand name Viread (R), JB Chemicals said in a communiqué on the Bombay Stock Exchange today.
Gilead would provide the technological know-how for active pharmaceutical ingredient (API) and the finished product and JB Chemicals would pay a royalty on net sales of the finished product to the US firm bio-pharmaceutical firm.
Experts on SiliconIndia
Post your Comment
All form fields are required.